Translation dysregulation in cancer as a source for targetable antigens
- PMID: 40154482
- PMCID: PMC12074880
- DOI: 10.1016/j.ccell.2025.03.003
Translation dysregulation in cancer as a source for targetable antigens
Abstract
Aberrant peptides presented by major histocompatibility complex (MHC) molecules are targets for tumor eradication, as these peptides can be recognized as foreign by T cells. Protein synthesis in malignant cells is dysregulated, which may result in the generation and presentation of aberrant peptides that can be exploited for T cell-based therapies. To investigate the role of translational dysregulation in immunological tumor control, we disrupt translation fidelity by deleting tRNA wybutosine (yW)-synthesizing protein 2 (TYW2) in tumor cells and characterize the downstream impact on translation fidelity and immunogenicity using immunopeptidomics, genomics, and functional assays. These analyses reveal that TYW2 knockout (KO) cells generate immunogenic out-of-frame peptides. Furthermore, Tyw2 loss increases tumor immunogenicity and leads to anti-programmed cell death 1 (PD-1) checkpoint blockade sensitivity in vivo. Importantly, reduced TYW2 expression is associated with increased response to checkpoint blockade in patients. Together, we demonstrate that defects in translation fidelity drive tumor immunogenicity and may be leveraged for cancer immunotherapy.
Keywords: cancer immunopeptidome; immune checkpoint blockade; neoantigens; non-canonical peptides; translation fidelity.
Copyright © 2025 The Author(s). Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests Y. Samuels, O.B., and C.W. hold patents related to TYW2. C.S.M. holds patents related to MULTI-seq. A.T.S. is a founder of Immunai, Cartography Biosciences, Santa Ana Biosciences, and Prox Biosciences, an advisor to 10× Genomics and Wing Venture Capital, and receives research funding from Merck Research Laboratories and Astellas Pharma. E.R. is a divested co-founder of Pangea Biomed and is a non-paid member of the scientific advisory boards of Pangea Biomed and GSK oncology.
References
- 
    - Deniger DC, Pasetto A, Robbins PF, Gartner JJ, Prickett TD, Paria BC, Malekzadeh P, Jia L, Yossef R, Langhan MM, et al. (2018). T-cell Responses to TP53 "Hotspot" Mutations and Unique Neoantigens Expressed by Human Ovarian Cancers. Clin Cancer Res 24, 5562–5573. 10.1158/1078-0432.CCR-18-0573. - DOI - PMC - PubMed
 
MeSH terms
Substances
Grants and funding
LinkOut - more resources
- Full Text Sources
- Medical
- Molecular Biology Databases
- Research Materials
 
        